We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$59.6M
Cap. Flow
-$61.6M
Cap. Flow %
-4.35%
Top 10 Hldgs %
62.23%
Holding
38
New
7
Increased
10
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$51.6M
2
RLAY icon
Relay Therapeutics
RLAY
+$39.7M
3
CDTX
Cidara Therapeutics
CDTX
+$28.2M
4
KYMR icon
Kymera Therapeutics
KYMR
+$25.8M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$22.8M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$62.3M
2
MRUS
Merus
MRUS
+$44.6M
3
SLNO
Soleno Therapeutics
SLNO
+$40.4M
4
VERA icon
Vera Therapeutics
VERA
+$39.6M
5
COGT icon
Cogent Biosciences
COGT
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.44%
2 Financials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$185M 13.09%
3,525,000
-947,840
-21% -$44.6M
NUVL
2
DELISTED
Nuvalent
NUVL
$105M 7.41%
1,375,000
-480,000
-26% -$35.1M
XENE icon
3
Xenon Pharmaceuticals
XENE
$6.32B
$94.7M 6.68%
3,025,000
+700,000
+30% +$22.8M
ELVN icon
4
Enliven Therapeutics
ELVN
$3.78B
$94.1M 6.64%
4,692,809
+17,809
+0.4% +$337K
AGIO icon
5
Agios Pharmaceuticals
AGIO
$2.16B
$77.3M 5.46%
2,325,000
+140,000
+6% +$4.24M
CLDX icon
6
Celldex Therapeutics
CLDX
$2.77B
$70.2M 4.96%
3,450,000
+250,000
+8% +$4.87M
ALKS icon
7
Alkermes
ALKS
$8.82B
$70.1M 4.95%
2,450,000
+500,000
+26% +$14.9M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.13B
$68.2M 4.81%
4,875,000
+1,275,000
+35% +$17.3M
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.75B
$59.4M 4.19%
+1,075,000
New +$51.6M
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$57.2M 4.04%
+1,175,000
New +$28.2M
SRRK icon
11
Scholar Rock
SRRK
$5.71B
$51.4M 3.63%
1,450,000
-295,000
-17% -$9.26M
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$51.1M 3.61%
610,000
-540,000
-47% -$40.4M
RLAY icon
13
Relay Therapeutics
RLAY
$4.02B
$46.2M 3.26%
+13,350,000
New +$39.7M
NRIX icon
14
Nurix Therapeutics
NRIX
$2.43B
$45M 3.17%
3,948,653
-30,254
-0.8% -$327K
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$43.3M 3.06%
3,298,289
+930,711
+39% +$11.8M
PHVS icon
16
Pharvaris
PHVS
$2.39B
$33.6M 2.37%
1,911,433
– –
KYMR icon
17
Kymera Therapeutics
KYMR
$9.1B
$32.7M 2.31%
+750,000
New +$25.8M
DFTX
18
Definium Therapeutics
DFTX
$5.73B
$32.5M 2.29%
5,000,000
+475,000
+10% +$3.12M
SYRE icon
19
Spyre Therapeutics
SYRE
$8.87B
$29.8M 2.1%
1,988,084
– –
TYRA icon
20
Tyra Biosciences
TYRA
$1.82B
$29.7M 2.09%
3,100,000
+2,150,000
+226% +$20.4M
VERA icon
21
Vera Therapeutics
VERA
$2.54B
$18.8M 1.33%
800,000
-1,761,782
-69% -$39.6M
CTMX icon
22
CytomX Therapeutics
CTMX
$705M
$17.5M 1.23%
+7,692,300
New +$12.4M
COGT icon
23
Cogent Biosciences
COGT
$6.79B
$16.6M 1.17%
2,311,164
-6,581,652
-74% -$36.5M
ORKA
24
Oruka Therapeutics
ORKA
$5.56B
$15.9M 1.12%
1,419,714
– –
DRUG
25
Bright Minds Biosciences
DRUG
$700M
$13.1M 0.92%
500,000
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Commodore Capital held 38 positions worth $1.42B, up 4.4% from $1.36B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Commodore Capital withdrew a net $61.6M in Q2 2025, closing 5 positions and reducing 8 holdings. Its most notable exit was Vaxcyte, an estimated $62.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Commodore Capital opened a new position in Protagonist Therapeutics worth $59.4M.

  • Commodore Capital's largest Q2 2025 buy was Protagonist Therapeutics: 1,075,000 shares worth $59.4M.
  • Commodore Capital added most to Xenon Pharmaceuticals in Q2 2025, an estimated $22.8M increase.
  • Commodore Capital's biggest Q2 2025 reduction was Merus, cutting an estimated $44.6M.
  • Commodore Capital fully exited Vaxcyte in Q2 2025, selling an estimated $62.3M.
  • Commodore Capital's ten largest holdings make up 62% of its $1.42B portfolio in Q2 2025.
  • Commodore Capital opened 7 new positions and closed 5 in Q2 2025.
  • Commodore Capital's portfolio value rose 4.4% quarter-over-quarter to $1.42B.

Based on Commodore Capital's 13F filing for Q2 2025, filed 14 Aug 2025.